SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
| FROM | TO | |
|---|---|---|
| RECCE PHARMACEUTICALS LTD | 17/01/2018 | |
| RECCE LIMITED | 17/01/2018 |
Level 5, 126 Philip Street Sydney NSW 2000 GPO Box 5193 Sydney NSW 2001
Tel : 1300 288 664 or +61 2 9698 5414The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately following the release by RCE of an announcement regarding the outcome of an application to the Supreme Court of New South Wales. | 12/10/2021 |
The Court made the orders sought by the company, namely: orders taht: the period of 5 business days in which to lodge the cleansing notice be extended to 8 October 2021; and the cleansing notice released on 8 October 2021 be deemed to take effect as if it had been lodged on 2 September 2021; a declaration that any offer for sale, or any sale of, any of the shares occurring in the period after their issue is not invalid by reason of any failure by the company or any shareholder to comply with the disclosure obligations; and orders that any person who made an offer of sale in respect of the shares, and any other person offering to sell or selling the shares is relieved from any civil liability arising out of any contravention in respect of the shares. | 12/10/2021 |
The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement regarding an application to the Supreme Court of New South Wales. | 12/10/2021 |
The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately, following the release by RCE of an announcement regarding anti-viral testing results. | 10/11/2020 |
RECCE 327, a synthetic anti-infective showed encouraging efficacy in an in-vitro screening assay against SARS-CoV-2 virus. This showed encouraging inhibition and is advancing to Stage 1b (confirmatory in vitro testing and a cytotoxicity assessment), underway in near weeks. U.S. in-vivo studies running in parallel are on track for data CY2020. | 10/11/2020 |
The Company requests that the voluntary suspension to remain in place until the earlier of the commencement of normal trading on Wednesday, 11 November 2020 or the release of an announcement by the Company in relation to the results. | 10/11/2020 |
The Company requests that the voluntary suspension to remain in place until the earlier of the commencement of normal trading on Tuesday, 10 November 2020 or the release of an announcement by the Company in relation to the results. | 09/11/2020 |
The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement relating to anti-viral testing results. | 05/11/2020 |
The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately following the release by RCE of an announcement regarding a material research agreement. | 08/07/2020 |
RECCE 327 and New RECCE® 529 compounds were selected for their unique mechanism of actions against hyper-mutation, as indicated on bacteria and viruses (respectively). Testing program will be conducted by CSIRO & University of Melbourne at the Doherty Institute. Therapeutic antiviral treatment focus of RECCE 327 and RECCE 529 may see added potential benefit against secondary bacterial infections. | 08/07/2020 |
The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement regarding a material research agreement. | 08/07/2020 |
name changed from Recce Limited | 17/01/2018 |
They're registered on Automic not Computershare | 30/04/2020 13:24:35 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 22/06/2023 | James Graham | 500,000 | $0.102 | $50,915.00 |
| 21/06/2021 | Michele Dilizia | -175,000 | $1.019 | $178,239.00 |
| 16/06/2021 | James Graham | 47,850 | $1.045 | $50,003.00 |
| 08/08/2019 | Michele Dilizia | -45,000 | $0.222 | $9,975.00 |
| 07/08/2019 | Michele Dilizia | -277,000 | $0.217 | $60,180.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| John Prendergast | Executive Chairman, Independent Director | 24/04/2018 |
| Justin Reynolds | CFO | 29/11/2017 |
| Alan Dunton | Independent Director | 14/07/2020 |
| Alistair McKeough | Non Exec Director | 01/09/2022 |
| James Graham | Executive Director, CEO | 15/01/2016 |
| Justin Ward | Executive Director | 09/07/2019 |
| Michele Dilizia | Executive Director | 15/01/2016 |
| Maggie Niewidok | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
